8月11日 - ** 制药公司沙特克实验室（Shattuck Labs， STTK.O）的股价在盘前交易中下跌1.8%，报7.01美元
** 该公司报告第二季度净亏损1520 万美元，而去年同期净亏损为 1250万美元
** STTK第二季度研发支出增长34%，至1170万美元
** 据伦敦证券交易所集团（LSEG）数据显示，分析师此前平均预期研发费用为1090万美元
** 截至6月30日，该公司持有2.083亿美元的现金、现金等价物及投资，预计可支持运营至2029年
** 该公司专注于开发针对炎症性及免疫介导性疾病的潜在治疗方案
** 截至上一交易日收盘，该股年内累计涨幅达95.6%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.